Jet Platform connects providers, patients and premium suppliers on a single set of rails — and keeps commerce, capital and clinical intelligence moving within them.
Across oncology, ophthalmology, dermatology, dentistry and aesthetics, providers purchase specialty drugs and devices themselves — then either charge patients directly or bill for reimbursement. It is an enormous share of specialty care, and it runs on fragmented distribution, opaque pricing and capital tied up at the practice level.
Botulinum toxin sits at the center of that picture. Roughly half of its use is therapeutic and reimbursed; the other half is aesthetic and paid in cash. One product exercises both halves of the model — which is why it is where Jet Platform begins, and not where it ends.
Jet Platform intermediates the transaction between providers, patients and a curated set of premium suppliers. Membership, stored value and embedded financing are built into the same system, so capital circulates on Jet's rails rather than leaking out to intermediaries at every step.
For suppliers, that means reach without channel conflict and pricing that holds. For providers, it means purchasing power, working capital and a commercial relationship that compounds rather than resets with every order.
Both were developed by Aquavit Pharmaceuticals AG in Zug, Switzerland — aquavit.ai — and are applied within Jet Platform's commercial operations.
Jurisdiction-specific regulatory and reimbursement intelligence, applied in real time. Specialty medicine is governed differently in every market it touches; this is what makes operating across them at scale tractable.
Orchestration of premium product distribution and demand — matching supply, territory and provider so that supplier volume grows without undermining the channel it depends on.
The platform is not a proposal. Its membership, ordering and fulfillment layers operate today as AQUAGOLD® VIP, serving professional accounts internationally — the aesthetics beachhead, where each mechanism is proven in commercial conditions before it is carried into the next specialty.
We work with a small number of suppliers, distributors and institutional partners. Correspondence from principals is welcome.